[go: up one dir, main page]

PL2187880T3 - Kompozycje i sposoby do leczenia zwyrodnienia plamki żółtej - Google Patents

Kompozycje i sposoby do leczenia zwyrodnienia plamki żółtej

Info

Publication number
PL2187880T3
PL2187880T3 PL08830106T PL08830106T PL2187880T3 PL 2187880 T3 PL2187880 T3 PL 2187880T3 PL 08830106 T PL08830106 T PL 08830106T PL 08830106 T PL08830106 T PL 08830106T PL 2187880 T3 PL2187880 T3 PL 2187880T3
Authority
PL
Poland
Prior art keywords
compositions
methods
macular degeneration
treating macular
treating
Prior art date
Application number
PL08830106T
Other languages
English (en)
Inventor
Ilyas Washington
Original Assignee
Univ Columbia
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40452355&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL2187880(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Univ Columbia filed Critical Univ Columbia
Publication of PL2187880T3 publication Critical patent/PL2187880T3/pl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/20Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/203Retinoic acids ; Salts thereof
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23LFOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/135Amines having aromatic rings, e.g. ketamine, nortriptyline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • A61K31/165Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0048Eye, e.g. artificial tears
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23VINDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00Food compositions, function of food ingredients or processes for food or foodstuffs

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Engineering & Computer Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Mycology (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Nutrition Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicines Containing Plant Substances (AREA)
PL08830106T 2007-09-12 2008-09-12 Kompozycje i sposoby do leczenia zwyrodnienia plamki żółtej PL2187880T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US99337907P 2007-09-12 2007-09-12
PCT/US2008/010676 WO2009035673A1 (en) 2007-09-12 2008-09-12 Compositions and methods for treating macular degeneration
EP08830106.4A EP2187880B1 (en) 2007-09-12 2008-09-12 Compositions and methods for treating macular degeneration

Publications (1)

Publication Number Publication Date
PL2187880T3 true PL2187880T3 (pl) 2014-05-30

Family

ID=40452355

Family Applications (1)

Application Number Title Priority Date Filing Date
PL08830106T PL2187880T3 (pl) 2007-09-12 2008-09-12 Kompozycje i sposoby do leczenia zwyrodnienia plamki żółtej

Country Status (8)

Country Link
US (4) US8877809B2 (pl)
EP (2) EP2687208A1 (pl)
JP (2) JP5149388B2 (pl)
DK (1) DK2187880T3 (pl)
ES (1) ES2449150T3 (pl)
PL (1) PL2187880T3 (pl)
PT (1) PT2187880E (pl)
WO (1) WO2009035673A1 (pl)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040242704A1 (en) 2003-03-14 2004-12-02 University Of Washington, Techtransfer - Invention Licensing Stabilized mutant opsin proteins
CN1988898B (zh) 2004-06-18 2012-12-26 华盛顿大学 用于治疗视觉障碍的视黄醛衍生物及其使用方法
PL2187880T3 (pl) 2007-09-12 2014-05-30 Univ Columbia Kompozycje i sposoby do leczenia zwyrodnienia plamki żółtej
JP6022746B2 (ja) 2008-02-11 2016-11-09 ユニヴァーシティ オブ ワシントン 加齢関連性網膜機能不全の治療及び予防方法
US20090312438A1 (en) * 2008-06-13 2009-12-17 Bernstein Paul S Compositions and Methods for Attenuating the Formation of A2E in the Retinal Pigment Epithelium
RU2546005C2 (ru) 2009-09-15 2015-04-10 Кью Эл Ти ИНК. Фармацевтические составы, содержащие 9-цис-ретиниловые сложные эфиры в липидном наполнителе
CA2796991A1 (en) 2010-04-19 2011-10-27 Qlt Inc. Therapeutic regimen and methods for treating or ameliorating visual disorders associated with an endogenous retinoid deficiency
EP2819667B8 (en) 2012-03-01 2020-03-04 Retinagenix Therapeutics, Inc. Retinal derivatives for use in improving visual function
EP2858648B1 (en) 2012-06-07 2018-08-22 Beth Israel Deaconess Medical Center, Inc. Methods and compositions for the inhibition of pin1
EP3105586B1 (en) * 2014-02-13 2021-08-04 Katairo GmbH Methods for the determination of compounds or compositions for the treatment of lipofuscin related diseases and compounds or compositions
US20170112792A1 (en) * 2014-03-21 2017-04-27 Beth Israel Deaconess Medical Center, Inc. Enhanced atra-related compounds derived from structure-activity relationships and modeling for inhibiting pin1
US10351914B2 (en) 2014-07-17 2019-07-16 Beth Israel Deaconess Medical Center, Inc. Biomarkers for Pin1-associated disorders
KR102276424B1 (ko) * 2014-10-06 2021-07-12 삼성전자주식회사 로-키나제 저해제를 포함하는 세포의 노화를 감소시키기 위한 조성물 및 그의 용도
US9173915B1 (en) 2014-10-10 2015-11-03 Peter F. Kador Antioxidant eye drops
US10548864B2 (en) 2015-03-12 2020-02-04 Beth Israel Deaconess Medical Center, Inc. Enhanced ATRA-related compounds for the treatment of proliferative diseases, autoimmune diseases, and addiction conditions
US20200025685A1 (en) * 2016-12-15 2020-01-23 Codiak Biosciences, Inc. Methods of measuring exosomes using intrinsic fluorescence
CN118121573A (zh) * 2022-12-01 2024-06-04 复旦大学 一种氘代维生素a及其衍生物的用途

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5310764A (en) 1992-05-08 1994-05-10 Steven Baranowitz Treatment of age related macular degeneration with beta-carotene
US5508456A (en) * 1993-07-30 1996-04-16 Ligand Pharmaceuticals Incorporated 9-cis tritium-labeled retinoids and intermediates, methods for their synthesis and methods for their use in discovering retinoid X receptor ligands
US5489611A (en) 1995-02-10 1996-02-06 Warner-Lambert Company Method for lowering plasma levels of lipoprotein (a)
US8198334B2 (en) 1997-10-27 2012-06-12 Pathologica Llc Methods for modulating macrophage proliferation in ocular disease using polyamine analogs
US6593104B1 (en) 1999-02-12 2003-07-15 University Of Iowa Research Foundation Macular degeneration diagnostics and therapeutics
US20030149997A1 (en) 1999-02-19 2003-08-07 Hageman Gregory S. Diagnostics and therapeutics for arterial wall disruptive disorders
CA2385475A1 (en) * 1999-08-16 2001-02-22 Human Genome Sciences, Inc. 18 human secreted proteins
US20040009907A1 (en) 2001-02-26 2004-01-15 Alsobrook John P. Proteins and nucleic acids encoding same
US20030032078A1 (en) 2001-01-23 2003-02-13 Board Of Regents, The University Of Texas System Methods and compositions for the treatment of macular and retinal degenerations
NZ516873A (en) 2001-02-12 2003-11-28 Warner Lambert Co Compositions containing retinoids and erb inhibitors and their use in inhibiting retinoid skin damage
EP1368296A1 (en) * 2001-03-14 2003-12-10 Eli Lilly And Company Fluorinated trienes and their use as rxr modulators
US6660297B2 (en) 2001-03-23 2003-12-09 Bausch & Lomb Incorporated Nutritional supplement to treat macular degeneration
US20040121407A1 (en) * 2002-09-06 2004-06-24 Elixir Pharmaceuticals, Inc. Regulation of the growth hormone/IGF-1 axis
CA2507036A1 (en) * 2002-12-02 2004-06-17 Genvec, Inc. Materials and methods for treating ocular-related disorders
EP1628631A2 (en) 2003-06-05 2006-03-01 Achkar, Charles C. Methods of treating hyperproliferative cell disorders
WO2005065669A1 (en) * 2003-12-19 2005-07-21 Alcon, Inc. Composition and methods for inhibiting the progression macular degeneration and promoting healthy vision
FR2864871A1 (fr) 2004-01-06 2005-07-08 Thomson Licensing Sa Methode de decouverte d'un reseau domestique et appareil implementant la methode
US7309487B2 (en) 2004-02-09 2007-12-18 George Inana Methods and compositions for detecting and treating retinal diseases
US7566808B2 (en) 2004-02-17 2009-07-28 President And Fellows Of Harvard College Management of ophthalmologic disorders, including macular degeneration
US9421175B2 (en) * 2004-03-17 2016-08-23 Lars Michael Larsen Prevention of retinopathy by inhibition of the visual cycle
US20060089411A1 (en) * 2004-08-07 2006-04-27 Gierhart Dennis L Treatment of Stargardt's disease and other lipofuscin disorders with combined retinaldehyde inhibitor and zeaxanthin
AU2005287343A1 (en) * 2004-08-18 2006-03-30 Sirion Therapeutics, Inc. Combination compositions comprising 13-cis-retinyl derivatives and uses thereof to treat opthalmic disorders
WO2006047475A2 (en) 2004-10-25 2006-05-04 Sytera, Inc. Detection and analysis of ophthalmically-relevant fluorescent molecules
EP1807103A4 (en) 2004-11-04 2009-02-11 Sirion Therapeutics Inc MODULATORS OF A COMPLEX RETINOL-RETINOL-BINDING PROTEIN-TRANSTHYRETINE FORMATION
AU2005314039B2 (en) 2004-12-08 2008-01-31 Revision Therapeutics, Inc. Methods, assays and compositions for treating retinol-related diseases
US20070014833A1 (en) * 2005-03-30 2007-01-18 Sirtris Pharmaceuticals, Inc. Treatment of eye disorders with sirtuin modulators
US20060292099A1 (en) 2005-05-25 2006-12-28 Michael Milburn Treatment of eye disorders with sirtuin modulators
EP1888548B1 (en) 2005-05-26 2012-08-22 Neuron Systems, Inc Quinoline derivative for the treatment of retinal diseases
UA81382C2 (en) * 2005-07-11 2007-12-25 Composition for treating retinol-related diseases by modulation of retinol binding
CN101316584A (zh) * 2005-09-27 2008-12-03 北海道公立大学法人札幌医科大学 用于预防及治疗由血管通透性亢进引起的眼病的医药
PL2187880T3 (pl) 2007-09-12 2014-05-30 Univ Columbia Kompozycje i sposoby do leczenia zwyrodnienia plamki żółtej
US8263601B2 (en) 2009-02-27 2012-09-11 Concert Pharmaceuticals, Inc. Deuterium substituted xanthine derivatives
EP2690092B1 (en) * 2009-06-18 2016-03-16 Concert Pharmaceuticals Inc. Deuterated isoindoline-1,3-dione derivatives as PDE4 and TNF-alpha inhibitors
WO2012057723A1 (en) 2009-10-22 2012-05-03 Proksch, Roger Thermal measurements using multiple frequency atomic force microscopy

Also Published As

Publication number Publication date
US9486432B2 (en) 2016-11-08
PT2187880E (pt) 2014-03-25
USRE47045E1 (en) 2018-09-18
US20150133549A1 (en) 2015-05-14
JP2013049711A (ja) 2013-03-14
US20170128403A1 (en) 2017-05-11
WO2009035673A8 (en) 2009-07-02
DK2187880T3 (da) 2014-03-10
JP2010539168A (ja) 2010-12-16
JP5695017B2 (ja) 2015-04-01
EP2687208A1 (en) 2014-01-22
US20110034554A1 (en) 2011-02-10
EP2187880B1 (en) 2013-12-18
ES2449150T3 (es) 2014-03-18
EP2187880A1 (en) 2010-05-26
JP5149388B2 (ja) 2013-02-20
WO2009035673A1 (en) 2009-03-19
EP2187880A4 (en) 2010-09-08
US8877809B2 (en) 2014-11-04

Similar Documents

Publication Publication Date Title
PT2187880E (pt) Composições e métodos para o tratamento da degenerescência macular
HRP20190214T1 (hr) Pripravci i metode za liječenje purpure
HRP20182135T1 (hr) Pripravci za i postupci liječenja poremećaja povezanih s ige
EP2170309A4 (en) METHOD AND COMPOSITIONS FOR THE TREATMENT OF DISEASES
SI3708178T1 (sl) Peptid za uporabo pri preprečevanju ali zdravljenju degeneracije makule
ZA200908711B (en) Methods and compositions for treating allergic diseases
IL202015A0 (en) Methods and compositions for treating skin conditions
IL193014A0 (en) Methods and compositions for treating schizophrenia
EP2120561A4 (en) COMPOSITIONS FOR TREATING BIOFILMS, AND METHODS FOR THEIR USE
IL251169A0 (en) Methods and preparations for stimulating the generation of nerve cells and inhibiting the degeneration of nerve cells through the use of isothiazolopyrimidinones
IL210097A0 (en) Compositions and methods for treating unfluenza
IL215932A0 (en) Compositions and methods for treating burns
GB2466912B (en) Compositions and methods for treating lysosomal disorders
ZA200900140B (en) Methods and compositions for treating biofilms
PL2252317T3 (pl) Leczenie zwyrodnienia plamki żółtej
IL173971A0 (en) Compositions and methods for treating and preventing age-related macular degeneration
HUP0700369D0 (en) Pharmaceutical compositions and method for treating schizofrenia
HRP20130642T1 (en) Methods and compositions for treating cancers
GB0625844D0 (en) The treatment of macular degeneration
WO2011097577A9 (en) Compositions and methods for treating or preventing retinal degeneration
ZA201108151B (en) Method and composition for treating macular degeneration
IL213550A0 (en) Method for treating macular degeneration
IL209947A0 (en) Compositions and methods for treating corneal inflammation
EP2237777A4 (en) COMPOSITIONS AND METHOD FOR THE TREATMENT OF NEURODEEGENERATIVE DISEASES
EP2094279A4 (en) METHOD AND COMPOSITIONS FOR THE TREATMENT OF INFLUENZA